Next Generation Sequencing Is Expected To Hold The Largest Share

In our study, we have segmented the next generation sequencing market by product, service, application and end-users. The products considered in the study are platform, services, and consumables. The platform segment is further segmented as Hiseq, Miseq, Solid, ION Torrent, Pacbio Rs II & Sequel Systems. The sub-segment of services is further divided as sequencing services and data management & analysis services. Consumables is further bifurcated as sample preparation consumables, library preparation & target enrichment kits & reagents, and quality control kits & reagents. The services segment is classified as genome sequencing. Exome sequencing, resequencing & targeted sequencing, and other services. The applications of next generation sequencing covered in the report include, diagnostics, drug discovery, precision medicine, and others. The end-users of next generation sequencing is classified as academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and others.

                                 Get Full Report Browser Click Here: https://bit.ly/2YDXXrp

The growth of next generation sequencing market is attributed to the substantial decline in the prices of sequencing. For example, the cost of sequencing in 2006 was around US $ 10 billion, which eventually dropped down to US$ 5,000 billion in 2012. Various market players such as Roche and Illumina have introduced sequencing techniques which have reduced the cost associated with sequencing. However, there are risks associated with genetic data which prove to be a major restraint in the market for next generation sequencing. One of the prominent risk associated is targeted marketing of drugs to individuals and family groups. Genetic data is also sold by companies to outside parties. For instance, 23andMe sold access to its database to around 13 other party pharmaceutical firms. Such risks associated with genetic data is likely to hamper growth of the market over the coming years. Recent developments in technologies has enabled companies to produce sequencing in a single day at the cost of about $15 per sample. It results in effective delivery of target and whole genome data for thousands of samples at a reasonable cost.